Want to see AIM full AI Analyst Report?
AIM Stock Chart & Stats
$0.25
>-$0.01(-0.40%)
At close: 4:00 PM EDT
$0.25
>-$0.01(-0.40%)
Day’s Range― - ―
52-Week Range$0.19 - $2.98
Previous CloseN/A
Volume270.87K
Average Volume (3M)2.14M
Market Cap
$7.25M
Enterprise Value-$1.18
Total Cash (Recent Filing)$9.96M
Total Debt (Recent Filing)$3.92M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 17, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.84
Shares Outstanding30,442,139
10 Day Avg. Volume547,025
30 Day Avg. Volume2,139,078
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.19
Price to Sales (P/S)20.78
P/FCF Ratio-0.16
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$5.25Price Target Upside2000.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.79
Revenue Forecast (FY)$61.00K
Bulls Say, Bears Say
Bulls Say
Clinical Manufacturing ReadinessExpanded manufacturing capacity and transferred test methods can improve supply reliability for ongoing and planned trials, reducing operational bottlenecks as AIM advances Ampligen toward larger clinical studies.
Listing Compliance And Capital SupportRestored exchange compliance and recently raised capital provide near-term organizational stability and funding for development activities, while reducing the immediate risk that listing problems disrupt access to investors.
Diversified Ampligen PipelineA platform spanning pancreatic cancer and emerging viral threats gives Ampligen multiple potential development paths. Orphan designations and prior safety data may support specialized regulatory and partnership opportunities, though efficacy remains unproven.
Bears Say
Minimal Revenue And Deep LossesA minimal revenue base and deeply negative gross, operating, and net profitability show that AIM has not established a commercial economic model. Sustained losses increase dependence on financing while clinical programs remain unproven.
Persistent Cash BurnConsistently negative operating and free cash flow means research, manufacturing, and trial spending are not funded internally. Continued cash burn could constrain development pace and require repeated external capital over the next several quarters.
Dilution And Financing DependenceBroad authorization for warrant, note-related, and other equity issuance preserves funding access but creates substantial dilution risk. The reverse-split flexibility and prior equity instability also indicate continuing dependence on capital markets.
AIM ImmunoTech News
AIM FAQ
What was Aim Immunotech Inc.’s price range in the past 12 months?
Aim Immunotech Inc. lowest stock price was $0.19 and its highest was $2.98 in the past 12 months.
What is Aim Immunotech Inc.’s market cap?
Aim Immunotech Inc.’s market cap is $7.25M.
When is Aim Immunotech Inc.’s upcoming earnings report date?
Aim Immunotech Inc.’s upcoming earnings report date is Aug 17, 2027 which is in 361 days.
How were Aim Immunotech Inc.’s earnings last quarter?
Aim Immunotech Inc. released its earnings results on Aug 10, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.17 by -$0.26.
Is Aim Immunotech Inc. overvalued?
According to Wall Street analysts Aim Immunotech Inc.’s price is currently Undervalued.
Does Aim Immunotech Inc. pay dividends?
Aim Immunotech Inc. pays a N/A dividend of $0.272 which represents an annual dividend yield of N/A. See more information on Aim Immunotech Inc. dividends here
What is Aim Immunotech Inc.’s EPS estimate?
Aim Immunotech Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aim Immunotech Inc. have?
Aim Immunotech Inc. has 30,442,139 shares outstanding.
What happened to Aim Immunotech Inc.’s price movement after its last earnings report?
Aim Immunotech Inc. reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.17. Following the earnings report the stock price went down -7.719%.
Which hedge fund is a major shareholder of Aim Immunotech Inc.?
Currently, no hedge funds are holding shares in AIM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aim Immunotech Inc.
AIM ImmunoTech Inc. (AIM) is a biotechnology company focused on immuno-oncology, antiviral, and immune-modulating therapeutics. The company’s core technology centers on nucleic-acid–based immune stimulators (including its lead investigational candidate, Ampligen/ritolimod) intended to activate innate immune pathways for potential use in cancer and infectious disease settings. AIM’s activities primarily involve research and development and advancing clinical and regulatory work for its drug candidates, rather than providing commercial healthcare services.
AIM Stock 12 Month Forecast
Average Price Target
$5.25
▲(2000.00% Upside)
Technical Analysis
Ownership Overview
0.30% Insiders
0.09% Mutual Funds
0.04% Other Institutional Investors
99.56% Public Companies and
Individual Investors